J&J Secures EU Approval for Tecvayli Combination as Second-Line Myeloma Therapy

Key Facts

1Johnson & Johnson's Tecvayli received EU approval for use with Darzalex as a second-line therapy for multiple myeloma patients.

2The approval is based on the MajesTEC-3 study, which showed significant improvements in progression-free and overall survival.

In a move that strengthens the company's oncology portfolio, Johnson & Johnson's Tecvayli has received European Union approval for use in combination with Darzalex as a second-line therapy for multiple myeloma patients. The approval is based on the MajesTEC-3 study, which demonstrated significant improvements in progression-free and overall survival compared to standard regimens. This regulatory milestone allows for the delivery of advanced immunotherapy options earlier in the patient's treatment journey.

This regulatory expansion follows a similar decision by the US FDA, broadening the addressable market for JNJ's hematology treatments. According to reports, combining the mechanisms of Tecvayli and Darzalex aims to enhance the immune system's response against cancer cells, a synergy reflected in study data showing durable outcomes for a vast majority of participating patients.

Regarding market performance, JNJ shares closed at $270.735 as of August 21, 2026, with a daily range between $267.04 and $272.655. While the immediate economic calendar lacks direct pharmaceutical sector catalysts, investors will monitor the market's absorption of this approval and its impact on biopharmaceutical revenue in upcoming quarters.

Sources:

pharmaphorum